Publications by authors named "P L Turecek"
Human migration is an increasingly common phenomenon and migrants are at risk of disadvantageous treatment. We reasoned that migrants may receive differential treatment by locals based on the closeness of their facial features to the host average. Residents of Türkiye, the country with the largest number of refugees currently, served as participants.
View Article and Find Full Text PDFArticle Synopsis
- Severe congenital protein C deficiency (SCPCD) is a rare, serious condition that leads to life-threatening blood issues shortly after birth, requiring effective treatment options.
- A targeted literature review summarized findings from 18 publications, primarily case studies, about long-term use of protein C concentrate (Ceprotin and Protexel) in managing SCPCD.
- Treatment with protein C concentrate showed generally positive outcomes, such as preventing complications and healing skin lesions, though dosing varied and some adverse effects were noted in limited cases.
Article Synopsis
- Accurate measurement of von Willebrand factor ristocetin cofactor activity (VWF:RCo) is essential for diagnosing von Willebrand disease and evaluating VWF products in the pharmaceutical industry, despite current high variability in lab results.
- A new automated method for determining VWF:RCo minimizes manual errors with a pre-dilution setup, leading to consistent results comparable to experienced technicians.
- This operator-independent protocol enhances standardization and efficiency in conducting VWF activity assays while maintaining high precision and accuracy.
One-third of humanity harbors a lifelong infection with , and probably about 80% are infected with human cytomegalovirus (CMV). This study aims to delineate the associations between toxoplasmosis and cognitive abilities and compare these to the associations with CMV. We evaluated the cognitive performance of 557 students, who had been examined for and CMV infections, using intelligence, memory, and psychomotor tests.
View Article and Find Full Text PDFIntroduction: Purified factor IX (FIX) concentrate (IMMUNINE, Takeda Manufacturing Austria AG, Vienna, Austria) is indicated for the treatment and prophylaxis of bleeding episodes in patients with congenital hemophilia B. Data on the use of purified FIX concentrate in patients ≤6 years old with congenital hemophilia B are limited.
Aim: Document real-world clinical experience with purified FIX concentrate in routine practice for pediatric patients with hemophilia B.